General Information
Alder Migraine 006
A Parallel Group Double-Blind Randomized Placebo Controlled Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Frequent Episodic Migraines.
| Protocol | ALD403-CLIN-006 |
|---|---|
| Identifier | Site Number: 192 |
| UID | 091da069-faf9-46e1-abfe-0d4915c9daa5 |
| Status | Done - Archived |
| Phase | 3 |
| Category | Migraine / Adult |
| Launch Year | 2016 |
| NCT Number | - |
| Created | 2016-07-27 12:29 |
| Last Updated | 2016-07-27 12:29 |
Description
No description provided.
Comment
PCRS
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2016-10-21 | No |
| Enrollment Open | 2016-09-06 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2016-08-16 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2018-02-13 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Sandoval, Larry | LSandoval | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Alder BioPharmaceuticals |
|---|---|
| Division | Alder BioPharmaceuticals |
| Team | Alder BioPharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | PPD Investigator Services, LLC |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
